Metabolize

NatLean: precision metabolite for satiety signaling

health AI / medtech / digital health (precision metabolismnutrition)

Visit website

StageSeed, Pre-Seed

Raised$500,000

Employees3

LocationSan Francisco, CA

About

Metabolize is pioneering a new category of human nutrition called precision metabolites. Precision metabolites deliver specific biological signals our bodies already use to regulate appetite and metabolism. No drugs. No injections. No brute force stimulation. This is not supplementation as usual. This is metabolic signaling, made precise.

Product

Value proposition: A precision metabolite designed to deliver body’s natural fullness signals to support satiety, especially after GLP-1 medications, enabling sustained weight management
Target customers: US healthcare consumers seeking weight management solutions and patients on GLP-1 therapies

Founders

Morris Laster — Co-Founder & CEO
Gideon Meir — Co-Founder & COO

Products

NatLean

Key features

precision metabolite signaling fullness and energy sufficiencydesigned to complement GLP-1 therapiestargets body’s natural satiety signalsnutrition that works with biology, not against it

Technologies

metabolomicsprecision metabolite designbiological signaling pathwaysendogenous metabolite targeting

Target conditions

weight managementobesitymetabolic health

Investors

SOSV

News

Q&A: Metabolize, A Solution to GLP-1 Rebound - SOSV · 2026-01-26T14:22:39.000Z
Metabolize - LinkedIn · 2026-01-30T00:00:00.000Z
Harnessing Our Own Bodies For Side Effect-Free Weight Loss · 2024-09-30T12:33:42.000Z
Metabolize Licenses Two Proprietary Metabolites to Address Obesity from Stanford OTL · 2024-07-30T17:16:00.000Z
Metabolize Unveils Groundbreaking Weight Reduction Metabolite, with Breakthrough Findings Published in Nature · 2024-09-10T13:00:00.000Z
Israel Startup Licenses Stanford Institute Metabolites To Develop... · 2024-09-01T00:00:00.000Z